Disability

Route 92 Medical Announces Expansion to New Manufacturing Site in Salt Lake City, Utah

SAN MATEO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated…

2 years ago

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa…

2 years ago

Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection

Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a…

2 years ago

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Study Conducted by Dr. Vince Clinical ResearchKANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a…

2 years ago

Dick and Betsy DeVos Family Foundation, SoldierStrong Donate Robotic Exoskeleton, Virtual Reality Treatment System to Help Vets Take Next Step Forward

ORLANDO, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) --  The Dick and Betsy DeVos Family Foundation and SoldierStrong today announced donations…

2 years ago

Study Finds Majority of Kentuckians Favor Universal Healthcare

LOUISVILLE, Ky., Oct. 24, 2022 (GLOBE NEWSWIRE) -- An overwhelming majority of Kentuckians favor a national government health plan, according…

2 years ago

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,…

2 years ago

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared…

2 years ago